

# Toshio Kubo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3614401/publications.pdf>

Version: 2024-02-01

79  
papers

1,206  
citations

471509

17  
h-index

434195

31  
g-index

80  
all docs

80  
docs citations

80  
times ranked

1693  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. <i>Internal Medicine</i> , 2022, 61, 379-383.	0.7	1
2	Identification of targetable kinases in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 20.	3.6	8
3	Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSCG 1801. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1139-1144.	2.2	7
4	Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3131-3131.	1.6	1
5	Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS12141-TPS12141.	1.6	0
6	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1111-1126.	3.4	10
7	Demand for weekend outpatient chemotherapy among patients with cancer in Japan. <i>Supportive Care in Cancer</i> , 2021, 29, 1287-1291.	2.2	4
8	Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSCG1406 trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 101-108.	1.1	7
9	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. <i>Respiratory Investigation</i> , 2021, 59, 240-246.	1.8	3
10	A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide. <i>International Cancer Conference Journal</i> , 2021, 10, 197-200.	0.5	1
11	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small cell lung cancers. <i>Cancer Science</i> , 2021, 112, 1853-1864.	3.9	29
12	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant <i>EGFR</i> and activated IGF1R. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 956-965.	1.3	6
13	A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3141-TPS3141.	1.6	2
14	Secretory carcinoma of the skin with lymph node metastases and recurrence in both lungs: A case report. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1069-1074.	1.3	4
15	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20590-e20590.	1.6	0
16	A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring <i>CCDC6</i> - <i>RET</i> fusion gene and <i>NF1</i> / <i>TP53</i> mutations. <i>Lung Cancer</i> , 2021, 156, 1-4.	2.0	7
17	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve <i>ALK</i> -, <i>ROS1</i> -, or <i>EGFR</i> -altered Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1653-1662.	4.1	7
18	Survival of chemo-naïve patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1269-1276.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR mutant lung cancer with HIF1 $\alpha$ /TGF $\beta$ expression. <i>Oncology Letters</i> , 2021, 22, 639.	1.8	1
20	Chemopreventive effects and anti-tumorigenic mechanisms of 2,6-dimethoxy-1,4-benzoquinone, a constituent of <i>Vitis coignetiae</i> Pulliat (crimson glory vine, known as yamabudo in Japan), toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J mice. <i>Food and Chemical Toxicology</i> , 2021, 154, 112319.	3.6	5
21	Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis. <i>Internal Medicine</i> , 2021, 60, 2967-2971.	0.7	2
22	Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1523-1532.	1.1	57
23	Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. <i>Acta Oncologica</i> , 2020, 59, 324-328.	1.8	2
24	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 249-256.	1.8	28
25	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2020, 532, 341-346.	2.1	10
26	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1447-1453.	1.3	14
27	Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	4
28	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2009-2018.	1.1	22
29	Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab. <i>Internal Medicine</i> , 2019, 58, 985-989.	0.7	25
30	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. <i>Respiratory Investigation</i> , 2019, 57, 460-465.	1.8	2
31	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 762-765.	1.3	43
32	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 458-464.	1.3	17
33	A phase I/II trial of weekly nab-paclitaxel for pretreated non-small cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 250-256.	1.1	3
34	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 54-58.	2.0	15
35	Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, 134-138.	2.6	19
36	Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial. <i>Journal of Clinical Oncology</i> , 2019, 37, e23105-e23105.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 287-290.	1.3	3
38	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. <i>Scientific Reports</i> , 2018, 8, 1955.	3.3	34
39	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 273-279.	1.1	119
40	Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. <i>Clinical Lung Cancer</i> , 2018, 19, e405-e415.	2.6	77
41	A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. <i>Lung Cancer</i> , 2018, 115, 103-108.	2.0	25
42	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 360-367.	2.1	15
43	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1906-1918.	1.1	88
44	Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. <i>Cancer Science</i> , 2018, 109, 3149-3158.	3.9	20
45	Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. <i>Clinical Lung Cancer</i> , 2018, 19, e861-e864.	2.6	27
46	The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, e21147-e21147.	1.6	2
47	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 29525-29531.	1.8	28
48	Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3119-TPS3119.	1.6	0
49	Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2018, 36, e21034-e21034.	1.6	0
50	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 434-437.	1.3	6
51	Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. <i>Molecular Oncology</i> , 2017, 11, 670-681.	4.6	14
52	Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. <i>Clinical Lung Cancer</i> , 2017, 18, 245-249.	2.6	8
53	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. <i>Lung Cancer</i> , 2017, 112, 188-194.	2.0	5
54	Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list. <i>Respiratory Investigation</i> , 2017, 55, 264-269.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. <i>Clinical Lung Cancer</i> , 2017, 18, 241-244.	2.6	9
56	Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9001-9001.	1.6	16
57	The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20601-e20601.	1.6	17
58	Chemoradiotherapy (CRT) for locally-advanced (LA) lung cancer patients with interstitial lung abnormalities (ILA).. <i>Journal of Clinical Oncology</i> , 2017, 35, e20057-e20057.	1.6	0
59	Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. <i>OncoTargets and Therapy</i> , 2016, 9, 1753.	2.0	4
60	Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 871-874.	1.3	17
61	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 941-947.	2.3	6
62	A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 769-774.	2.3	7
63	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-“Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). <i>Clinical Lung Cancer</i> , 2016, 17, 602-605.	2.6	10
64	Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 529-533.	1.3	2
65	Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. <i>International Journal of Clinical Oncology</i> , 2016, 21, 81-87.	2.2	26
66	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10100-10100.	1.6	0
67	Association with consolidation chemotherapy after concurrent chemoradiotherapy followed by surgery and the disease free survival in patients with stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20053-e20053.	1.6	0
68	Downregulation of TBXAS 1 in an iron-induced malignant mesothelioma model. <i>Cancer Science</i> , 2015, 106, 1296-1302.	3.9	14
69	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121211.	2.5	16
70	Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung Cancer. <i>Respiratory Investigation</i> , 2015, 53, 93-97.	1.8	18
71	Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-“Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001. <i>Journal of Thoracic Oncology</i> , 2015, 10, 486-491.	1.1	93
72	Phase II study of topotecan and cisplatin with sequential radiotherapy in elderly small cell lung cancer patients (Okayama Lung Cancer Study Group; OLCSG 0102).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7572-7572.	1.6	1

#	ARTICLE	IF	CITATIONS
73	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy. <i>Okayama Igakwai Zasshi</i> , 2015, 127, 127-132.	0.0	1
74	Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. <i>American Journal of Cancer Research</i> , 2015, 5, 1553-7.	1.4	11
75	Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2401.	4.3	3
76	A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801. <i>European Journal of Cancer</i> , 2014, 50, 2783-2790.	2.8	18
77	Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19102-e19102.	1.6	0
78	Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19084-e19084.	1.6	0
79	Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 589-597.	4.1	62